ClinicalTrials.gg
CompletedNCT02423122Updated Jun 14, 2019Results posted

A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

A Phase 2 interventional study of VX-745 in Alzheimer's Disease and Mild Cognitive Impairment, sponsored by EIP Pharma Inc. Completed at 1 site in Netherlands. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-06-14.

Sponsored by EIP Pharma Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 134 studies in Alzheimer Disease with a site in Netherlands — 17 open to participants now, 28 under way, 10 of them phase 3. Alzheimer Disease · Netherlands.

Enrollment
112th of 120
16 · median 246
Started
2015
with 9 others
Phase 2
31 of 134
1 open now
Registered
51st of 134
by date

Among the 134 studies in Alzheimer Disease with a site in Netherlands, this one is the 112th largest by enrollment of the 120 interventional ones that give a count, is one of 10 that started in 2015, is one of 31 in phase 2, and was the 51st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

17 of the 134 studies in Alzheimer Disease with a site in Netherlands are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Alzheimer Disease with a site in Netherlands, or all of them as a file.
02

Study summary

This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD). Subjects who meet entry criteria will undergo 11C-PiB (Carbon-11-labeled Pittsburgh Compound B) positron emission tomography (PET) at baseline and after 45 days of dosing with VX-745. Cognitive testing will also be conducted at baseline and day 45.

03

Conditions studied

  • Alzheimer's Disease
  • Mild Cognitive Impairment
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide
  • Diagnosis of mild cognitive impairment (MCI) due to probable AD or of mild AD
  • range: 20 to 28
  • Evidence of amyloid pathology by amyloid PET scan
  • Participants may be taking medications for AD, provided that the dose of these medications has been stable for >3 months
  • Proficiency in Dutch and adequate visual and auditory abilities to be able to perform all aspects of the cognitive and functional tests
  • Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.

Exclusion criteria

Exclusion Criteria:

  • Evidence of neurodegenerative disease other than AD
  • Inability for any reason to undergo PET and fMRI scans (including notably: history of allergic reaction of any severity to 11C-PiB injection; pacemaker, vascular stent or stent graft)
  • Psychiatric disorder that would compromise ability to comply with study requirements
  • Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder or metabolic/endocrine disorders or other disease that would preclude treatment with p38 MAP kinase inhibitor and/or assessment of drug safety and efficacy
  • Recent (\<90 days) changes to AD medications prescribed for cognitive reasons or with the potential to impact cognition
  • Participation in a study of an drug less than 6 months or 5 half-lives of the investigational drug, whichever is longer, before enrollment in the study
  • Male subjects with female partner of who are unwilling or unable to adhere to requirements
  • Female subjects who have not reached menopause or have not had a hysterectomy or bilateral oophorectomy/salpingoophorectomy
  • Positive urine or serum pregnancy test or plans desires to become pregnant during the course of the trial
  • Any factor deemed by the investigator to be likely to interfere with study conduction
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    VX-745 dose 1

    Active Group 1: VX-745 40 mg twice daily

    Drug: VX-745

  • Experimental
    VX-745 dose 2

    Active Group 2: VX-745 125 mg twice daily

    Drug: VX-745

Interventions

  • DrugVX-745

    Orally-Active Selective P45 MAP Kinase inhibitor

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET

    Percent change in global cortical amyloid specific PET signal (BPND)

    Time frame: Baseline compared to following 12 weeks' dosing with VX-745

  2. Number of 11C-PiB Responders

    Number of patients meeting protocol pre-specified definition of response: \> 7% reduction in global cortical BPND

    Time frame: Day 84

Secondary outcomes

  1. Wechsler Memory Scale (WMS) Immediate Recall Composite

    WMS immediate-recall composite score consisted of the sum of the scores on Logical Memory I, Verbal Paired Associates I, and Visual Reproduction I. The composite score ranges from 0 to 136; with higher score indicating better performance.

    Time frame: Baseline to Day 84

  2. Wechsler Memory Scale (WMS) Delayed Recall Composite

    WMS delayed-recall composite score at each testing sessions consisted of the sum of the scores on Logical Memory II, Verbal Paired Associates II, and Visual Reproduction II. The composite score ranges from 0 to 136; with higher scores indicating better performance.

    Time frame: Change from baseline to Day 84

07

Results

Posted Jun 14, 2019

Participant flow

Participant flow — Overall Study
MilestoneNeflamapimod (VX-745) Dose 1Neflamapimod (VX-745) Dose 2
Started97
Completed97
Not completed00

Outcome measures

PrimaryPercent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET

Percent change in global cortical amyloid specific PET signal (BPND)

Time frame:
Baseline compared to following 12 weeks' dosing with VX-745
Reported as:
Median · percentage change from baseline
Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET
percentage change from baselineNeflamapimod (VX-745) Dose 1Neflamapimod (VX-745) Dose 2
Percent Change From Baseline in Amyloid Plaque Burden by 11C-PiB PET-4.57 (-11.65 to 4.83)4.57 (0.56 to 12.25)
PrimaryNumber of 11C-PiB Responders

Number of patients meeting protocol pre-specified definition of response: \> 7% reduction in global cortical BPND

Time frame:
Day 84
Reported as:
Count of participants · Participants
Number of 11C-PiB Responders
ParticipantsNeflamapimod (VX-745) Dose 1Neflamapimod (VX-745) Dose 2
Number of 11C-PiB Responders31
SecondaryWechsler Memory Scale (WMS) Immediate Recall Composite

WMS immediate-recall composite score consisted of the sum of the scores on Logical Memory I, Verbal Paired Associates I, and Visual Reproduction I. The composite score ranges from 0 to 136; with higher score indicating better performance.

Time frame:
Baseline to Day 84
Reported as:
Mean · units on a scale
Wechsler Memory Scale (WMS) Immediate Recall Composite
units on a scaleNeflamapimod (VX-745) Dose 1Neflamapimod (VX-745) Dose 2
Wechsler Memory Scale (WMS) Immediate Recall Composite7.0 ± 11.013.4 ± 12.2
SecondaryWechsler Memory Scale (WMS) Delayed Recall Composite

WMS delayed-recall composite score at each testing sessions consisted of the sum of the scores on Logical Memory II, Verbal Paired Associates II, and Visual Reproduction II. The composite score ranges from 0 to 136; with higher scores indicating better performance.

Time frame:
Change from baseline to Day 84
Reported as:
Mean · units on a scale
Wechsler Memory Scale (WMS) Delayed Recall Composite
units on a scaleNeflamapimod (VX-745) Dose 1Neflamapimod (VX-745) Dose 2
Wechsler Memory Scale (WMS) Delayed Recall Composite7.5 ± 7.010.4 ± 11.9

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
40 mg Dose Group0/9 (0%)0/9 (0%)6/9 (66.7%)
125 mg Dose Group0/7 (0%)0/7 (0%)3/7 (42.9%)
Most frequent other events
Most frequent other events
Event40 mg Dose Group125 mg Dose Group
DiarrheaGastrointestinal disorders3/90/7
SomnolenceNervous system disorders1/91/7
Abdominal painGastrointestinal disorders1/91/7
Influenza like illnessGeneral disorders1/91/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Neflamapimod (VX-745) Dose 1Neflamapimod (VX-745) Dose 2Total
Median68 (60 to 76)65 (60 to 75)66.5 (60 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Neflamapimod (VX-745) Dose 1Neflamapimod (VX-745) Dose 2Total
Female246
Male7310
Region of Enrollment
Region of Enrollment(participants)Neflamapimod (VX-745) Dose 1Neflamapimod (VX-745) Dose 2Total
Netherlands9716
08

Study locations

1 site
  • Alzheimer Research Center, VU Medical Center
    Amsterdam, 1081 HV, Netherlands
09

References and documents

Publications

  • Tormahlen NM, Martorelli M, Kuhn A, Maier F, Guezguez J, Burnet M, Albrecht W, Laufer SA, Koch P. Design and Synthesis of Highly Selective Brain Penetrant p38alpha Mitogen-Activated Protein Kinase Inhibitors. J Med Chem. 2022 Jan 27;65(2):1225-1242. doi: 10.1021/acs.jmedchem.0c01773. Epub 2021 May 11. PubMed 33974419 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Jul 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2019, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2015
First posted
Apr 22, 2015
Start
Apr 2015
Primary completionActual
Jul 2016
CompletionActual
Sep 2016
Results first posted
Jun 14, 2019
Last update
Jun 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02423122
Lead sponsor
EIP Pharma Inc
Responsible party
Sponsor
First posted
Apr 22, 2015
Start date
Apr 2015
Primary completion
Jul 2016
Completion
Sep 2016
Results posted
Jun 14, 2019
Last update
Jun 14, 2019

Study contacts

Philip Scheltens, MD
principal investigator · Alheimer Research Center, VU medisch centrum

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VX-745

Start the discussion